Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency

Clinical Endocrinology

Volumn 64, Issue 5, 2006, Pages 549-555

  Yuen, Kevin C J ^a   Dunger, David B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN SENSITIVITY; LOW DRUG DOSE; MALE; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; C-PEPTIDE; DRUG ADMINISTRATION SCHEDULE; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 33646004291     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02507.x     Document Type: Article

References (37)

1. Bates A.S. Van't Hoff W. Jones P.J. Clayton R.N. 1996 The effect of hypopituitarism on life expectancy. Journal of Clinical Endocrinology and Metabolism 81 1169 1172.
2. Bulow B. Hagmar L. Mikoczy Z. Nordstrom C.H. Erfurth E.M. 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology 46 75 81.
3. Rosen T. Bengtsson B.A. 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336 285 288.
4. Tomlinson J.W. Holden N. Hills R.K. Wheatley K. Clayton R.N. Bates A.S. Sheppard M.C. Stewart P.M. 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357 425 431.
5. Beshyah S.A. Johnston D.G. 1999 Cardiovascular disease and risk factors in adults with hypopituitarism. Clinical Endocrinology 50 1 15.
6. McCallum R.W. Petrie J.R. Dominiczak A.F. Connell J.M.C. 2002 Growth hormone deficiency and vascular risk. Clinical Endocrinology 57 11 24.
7. McCallum R.W. Sainsbury C.A. Spiers A. Dominiczak A.F. Petrie J.R. Sattar N. Connell J.M. 2005 Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clinical Endocrinology 62 473 479.
8. Maison P. Griffin S. Nicoue-Beglah M. Haddad N. Balkau B. Chanson P. 2004 Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism 89 2192 2199.
9. Gola M. Bonadonna S. Doga M. Giustina A. 2005 Clinical review: growth hormone and cardiovascular risk factors. Journal of Clinical Endocrinology and Metabolism 90 1864 1870.
10. Bramnert M. Segerlantz M. Laurila E. Daugaard J.R. Manhem P. Groop L. 2003 Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. Journal of Clinical Endocrinology and Metabolism 88 1455 1463.
11. Rosenfalck A.M. Maghsoudi S. Fisker S. Jorgensen J.O. Christiansen J.S. Hilsted J. Volund A.A. Madsbad S. 2000 The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 85 4173 4181.
12. O'Neal D.N. Kalfas A. Dunning P.L. Christopher M.J. Sawyer S.D. Ward G.M. Alford F.P. 1994 The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. Journal of Clinical Endocrinology and Metabolism 79 975 983.
13. Hana V. Silha J.V. Justova V. Lacinova Z. Stepan J.J. Murphy L.J. 2004 The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clinical Endocrinology 60 442 450.
14. Hoffman A.R. Kuntze J.E. Baptista J. Baum H.B. Baumann G.P. Biller B.M. Clark R.V. Cook D. Inzucchi S.E. Kleinberg D. Klibanski A. Phillips L.S. Ridgway E.C. Robbins R.J. Schlechte J. Sharma M. Thorner M.O. Vance M.L. 2004 Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 89 2048 2056.
15. de Boer H. Blok G.J. Popp-Snijders C. Stuurman L. Baxter R.C. van der Veen E. 1996 Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. Journal of Clinical Endocrinology and Metabolism 81 1371 1377.
16. Ekman B. Lindstrom T. Nystrom F. Olsson A.G. Toss G. Arnqvist H.J. 2002 A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults. European Journal of Endocrinology 147 49 57.
17. GHRS 1998 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society (GHRS) Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism 83 379 381.
18. Yuen K.C.J. Frystyk J. White D.K. Twickler T.B. Koppeschaar H.P. Harris P.E. Fryklund L. Murgatroyd P.R. Dunger D.B. 2005 Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone dose in adults with severe growth hormone deficiency. Clinical Endocrinology 63 428 436.
19. Yuen K. Frystyk J. Umpleby M. Fryklund L. Dunger D. 2004 Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. Journal of Clinical Endocrinology and Metabolism 89 3956 3964.
20. WHO 1999 ) World Health Organisation, Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. World Health Organisation, Department of Noncommunicable Disease Surveillance, Geneva (1999).
21. Baum H.B. Biller B.M. Finkelstein J.S. Cannistraro K.B. Oppenhein D.S. Schoenfeld D.A. Michel T.H. Wittink H. Klibanski A. 1996 Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Annals of Internal Medicine 125 883 890.
22. Levy J.C. Matthews D.R. Hermans M.P. 1998 Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 2191 2192.
23. Matthews D.R. Hosker J.P. Rudenski A.S. Naylor B.A. Treacher D.F. Turner R.C. 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 412 419.
24. Haffner S.M. Miettinen H. Stern M.P. 1997 The homeostasis model in the San Antonio Heart Study. Diabetes Care 20 1087 1092.
25. Hermans M.P. Levy J.C. Morris R.J. Turner R.C. 1999 Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42 678 687.
26. Bonora E. Targher G. Alberiche M. Bonadonna R.C. Saggiani F. Zenere M.B. Monauni T. Muggeo M. 2000 Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 57 63.
27. Wallace T.M. Levy J.C. Matthews D.R. 2004 Use and abuse of HOMA modeling. Diabetes Care 27 1487 1495.
28. Wallace T.M. Matthews D.R. 2002 The assessment of insulin resistance in man. Diabetic Medicine 19 527 534.
29. Wolthers T. Hoffman D.M. Nugent A.G. Duncan M.W. Umpleby M. Ho K.K. 2001 Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. American Journal of Physiology-Endocrinology and Metabolism 281 E1191 E1196.
30. Cook D.M. Ludlam W.H. Cook M.B. 1999 Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 84 3956 3960.
31. Sakai K. Lowman H.B. Clemmons D.R. 2002 Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture. Journal of Biological Chemistry 277 13620 13627.
32. Moses A.C. Morrow L.A. O'Brien M. Moller D.E. Flier J.S. 1995 Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Research and Clinical Practice 28 Suppl. S185 S194.
33. Lemieux I. Pascot A. Prud'homme D. Almeras N. Bogaty P. Nadeau A. Bergeron J. Despres J.P. 2001 Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arteriosclerosis, Thrombosis and Vascular Biology 21 961 967.
34. Mohamed-Ali V. Goodrick S. Rawesh A. Katz D.R. Miles J.M. Yudkin J.S. Klein S. Coppack S.W. 1997 Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. Journal of Clinical Endocrinology and Metabolism 82 4196 4200.
35. Biller B.M. Sesmilo G. Baum H.B. Hayden D. Schoenfeld D. Klibanski A. 2000 Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 85 970 976.
36. Colao A. di Somma C. Rota F. Pivonello R. Savanelli M.C. Spiezia S. & L. 2005 Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism 90 2056 2062.
37. Nielsen S. Moller N. Christiansen J.S. Jorgensen J.O. 2001 Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 50 2301 2308.